可控基因疗法启动人体试验，目标逆转青光眼
A biotechnology company has started the first human trial of a gene therapy for glaucoma. The aim is to partially restore youthful function to aging eye cells. This method, called partial reprogramming, tries to regenerate damaged optic nerve cells. It is a new way to fight age-related diseases at their root.
一家生物技术公司已开始针对青光眼进行基因疗法的首次人体试验。该疗法旨在部分恢复衰老眼细胞的年轻功能。这种方法被称为“部分重编程”，试图再生受损的视神经细胞，为从根源上对抗年龄相关疾病提供了新途径。
Partial reprogramming temporarily activates genes that make cells act younger. These genes reset the cell's age, but only partway. Instead of turning the cell into a stem cell, the process stops early. As a result, optic nerve cells regain some repair ability without losing their identity. A harmless virus delivers these genes into the eye.
部分重编程会暂时激活使细胞表现得更年轻的基因。这些基因将细胞的年龄重置，但仅重置到一定程度。该过程不会将细胞转化为干细胞，而是中途停止。因此，视神经细胞在保留其身份的同时恢复了部分修复能力。无害病毒负责将这些基因递送至眼部。
Inspired by Scientific American reporting · Rewritten by Vocabsavvy · Vocabsavvy Original (inspired-by attribution)